QuantaMatrix Inc. (KOSDAQ:317690)

Market Cap	77.62B +9.1%
Revenue (ttm)	3.69B +47.7%
Net Income	-19.46B
EPS	-1,052.00
Shares Out	20.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,189
Average Volume	128,216
Open	3,875.00
Previous Close	3,890.00
Day's Range	3,815.00 - 4,030.00
52-Week Range	2,920.00 - 6,550.00
Beta	0.14
RSI	49.31
Earnings Date	Apr 3, 2026

About QuantaMatrix

QuantaMatrix Inc. operates as an in-vitro diagnostics company in South Korea. Its products include dRAST, a direct and rapid antimicrobial susceptibility test for treating sepsis that provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture; QDST, a rapid phenotypic drug susceptibility testing system for tuberculosis; QPLEX Alz plus assay, an early diagnosis kit for Alzheimer's disease; and Quanti9 and QuantiGal, a prognostic prediction kit for cardiovascular diseases. QuantaMatrix Inc. was founded i...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 317690

Financial Performance

In 2025, QuantaMatrix's revenue was 3.69 billion, an increase of 47.70% compared to the previous year's 2.50 billion. Losses were -19.46 billion, -3.51% less than in 2024.